Cure My Disease

Don't miss your cure!

 Log in / Sign up

App-based symptom tracking may cut hospital visits for advanced cancer patients

NCT ID NCT04611867

Symptom relief Sponsor: Inna Chen, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This trial tests a supportive web-based app for people with advanced pancreatic, biliary tract, or non-small cell lung cancer who are about to start their first line of chemotherapy. Each week, participants answer questions about their symptoms using the app. If their answers suggest a problem, a nurse contacts them to check in and offer advice on managing symptoms. The study aims to see if this approach is practical and whether it can reduce unplanned hospitalizations and improve quality of life during cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A supportive web-based application with integrated weekly patient-reported outcome questionnaires
What this could lead to
If it works, this app-based approach could help people with advanced pancreatic or lung cancer manage symptoms at home, avoid unplanned hospital stays, and maintain a better quality of life during treatment.
What could go wrong
This is an early feasibility study, so the app may not prove practical or effective in a larger group. Success depends on patients consistently reporting symptoms and nurses responding quickly, which may not always happen in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 274 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2021

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult (aged 18 and over) * Confirmed by cytology or histology advanced lung (NSCLC) or pancreatic cancer * Written informed consent before any study procedures * Planning to receive 1st line systemic anticancer therapy within ≤2 weeks * Performance status: ECOG 0-2 * Access to the internet * Ability to read and respond to questions or able to complete questions with minimal assistance required from an interpreter or family member Exclusion Criteria: * No mobile device * Exhibiting signs of overt psychopathology or cognitive dysfunction * Any medical condition that the Investigator considers significant to compromise the safety of the patient or that impairs the interpretation of study assessments * Patient participating in another interventional study during the surveillance period. This is only relevant for studies that might interfere with the intervention. Participation in protocols related only to treatment will not preclude participation in the present study. Cases of doubt will be settled by the protocol responsible.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biliary tract cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer malignant pancreatic neoplasm non-small cell lung carcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer, nonsmall cell Pancreatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Herlev & Gentofte University Hospital, Denmark

    RECRUITING

    Herlev, 2730, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.